Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | BMC Neurology

Fig. 2

From: Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Fig. 2

Global response over 3 years of ChEI treatment. The proportion of improved/unchanged participants in global performance (CIBIC score, 1–4) from the initiation of ChEIs over 3 years according to AT(N) biomarker profile. A higher frequency of improved/unchanged patients was exhibited in A+ T– (N)– after 12 months (p = 0.034), 30 months (p = 0.005) and 36 months (p = 0.029) of therapy. No significant difference in AT(N) profiles was found between the improved vs. the unchanged individuals at any assessment. Abbreviations: A+, abnormal CSF Aβ42; ChEI, cholinesterase inhibitor; CIBIC, Clinician Interview-Based Impression of Change; CSF, cerebro-spinal fluid; (N)–, normal CSF T-tau; (N)+, abnormal CSF T-tau; T–, normal CSF P-tau; T+, abnormal CSF P-tau

Back to article page